晚期钆增强范围可预测射血分数降低的非缺血性心肌病患者的不良心脏结局:一项前瞻性观察性研究
前瞻性纳入78例左室射血分数<35%的非缺血性心肌病患者,分析心脏磁共振晚期钆增强(LGE)范围与5年内主要不良心脏事件(MACE)的关系。LGE范围>12.0 %LV独立关联MACE(校正HR 6.71,95%CI 2.54-17.74,p<0.001),LGE≥12.0 %LV者MACE发生率51.4%,LGE≤12.0 %LV者20.9%(log-rank p=0.001)。
要点
- LGE范围>12.0 %LV是非缺血性心肌病伴左室射血分数<35%患者MACE的独立预测因子(校正HR 6.71)。
- LGE≥12.0 %LV者5年内MACE发生率为51.4%,LGE≤12.0 %LV者为20.9%,无事件生存率区分良好。
- 80.8%(63/78)的患者存在LGE,发生MACE者心肌瘢痕范围显著高于无事件者(22.0 vs 6.7 %LV,p=0.008)。
核心结论
- 在左室收缩功能显著降低的非缺血性心肌病患者中,LGE范围是长期不良心脏结局的强预测因子。
- LGE截止值12.0 %LV能良好区分无事件生存。
研究设计与样本
- 前瞻性观察性队列研究,纳入78例非缺血性心肌病且左室射血分数<35%的患者。
- 采用心脏磁共振分析晚期钆增强(LGE)的存在与范围。
- 主要结局为主要不良心脏事件(MACE),定义为入组后5年内 cardiac death、心脏移植、因主要心律失常的植入式心律转复除颤器放电、因充血性心力衰竭住院的复合终点。
关键影像表现/征象
- 80.8%(n=63)的患者存在LGE,中位左室射血分数为25.4%(19.8-32.4%)。
- 发生MACE者心肌瘢痕范围显著高于无心脏事件者(22.0 [5.5-46.1] %LV vs 6.7 [0-17.1] %LV,p=0.008)。
诊断标准与关键数值
- LGE≥12.0 %LV者MACE发生率为51.4%,LGE≤12.0 %LV者为20.9%(log-rank p=0.001)。
- 多因素分析显示LGE范围>12.0 %LV独立关联MACE(校正HR 6.71,95%CI 2.54-17.74,p<0.001)。
临床应用与阅片要点
- 在非缺血性心肌病伴左室射血分数<35%的患者中,可测量LGE范围并以12.0 %LV为参考截止值评估长期不良心脏结局风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The clinical course of an individual patient with heart failure is unpredictable with left ventricle ejection fraction (LVEF) only. We aimed to evaluate the prognostic value of cardiac magnetic resonance (CMR)-derived myocardial fibrosis extent and to determine the cutoff value for event-free survival in patients with non-ischemic cardiomyopathy (NICM) who had severely reduced LVEF.
MATERIALS AND METHODS: Our prospective cohort study included 78 NICM patients with significantly reduced LV systolic function (LVEF < 35%). CMR images were analyzed for the presence and extent of late gadolinium enhancement (LGE). The primary outcome was major adverse cardiac events (MACEs), defined as a composite of cardiac death, heart transplantation, implantable cardioverter-defibrillator discharge for major arrhythmia, and hospitalization for congestive heart failure within 5 years after enrollment.
RESULTS: A total of 80.8% (n = 63) of enrolled patients had LGE, with the median LVEF of 25.4% (19.8-32.4%). The extent of myocardial scarring was significantly higher in patients who experienced MACE than in those without any cardiac events (22.0 [5.5-46.1] %LV vs. 6.7 [0-17.1] %LV, respectively, p = 0.008). During follow-up, 51.4% of patients with LGE ≥ 12.0 %LV experienced MACE, along with 20.9% of those with LGE ≤ 12.0 %LV (log-rank p = 0.001). According to multivariate analysis, LGE extent more than 12.0 %LV was independently associated with MACE (adjusted hazard ratio, 6.71; 95% confidence interval, 2.54-17.74; p < 0.001).
CONCLUSION: In NICM patients with significantly reduced LV systolic function, the extent of LGE is a strong predictor for long-term adverse cardiac outcomes. Event-free survival was well discriminated with an LGE cutoff value of 12.0 %LV in these patients.
引用
- Kim EK, Lee GY, Jang SY, et al. The Extent of Late Gadolinium Enhancement Can Predict Adverse Cardiac Outcomes in Patients with Non-Ischemic Cardiomyopathy with Reduced Left Ventricular Ejection Fraction: A Prospective Observational Study. Korean J Radiol. 2020. PMID: 32932562. doi:10.3348/kjr.2020.0082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。